Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

Thymidylate synthase (TS) is a key enzyme in DNA synthesis and is inhibited by metabolites of the chemotherapeutic agent 5-fluorouracil (5FU). Nuclear expression of TS in human tissue in vivo has not been characterised and its clinicopathological correlates in malignancy are unknown. 52 cases of primary colorectal carcinoma (CRC) and 24 cases of matched metastatic carcinoma were studied immunohistochemically using the monoclonal antibody TS106. The degree of nuclear TS immunostaining correlated closely with levels of TS mRNA expression amongst 10 CRCs studied. Strong nuclear immunostaining was seen in normal basal crypt colonocytes and germinal centre cells, and in a varying proportion of adenocarcinoma cells. Amongst the primary carcinomas, higher TS nuclear expression was associated with prominent extracellular mucin production and right-sided location. Higher TS nuclear expression also showed a significant association with poorer response to protracted venous infusional 5FU therapy. There was no clear association between TS nuclear expression and Ki67 or p53 expression assessed immunohistochemically. There was a strong positive correlation between TS nuclear expression in primary and metastatic CRC but the latter generally showed higher expression than matched primary tumour tissue. These findings confirm the nuclear expression of TS protein in human cells in vivo and provide new insight into how such expression may relate to the behaviour of CRCs. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  J. Cummings,et al.  5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer , 2001, British Journal of Cancer.

[2]  F. Maley,et al.  Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  L. Aaltonen,et al.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. , 2000, Gastroenterology.

[4]  David Joseph,et al.  Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer , 2000, The Lancet.

[5]  F. Révillion,et al.  Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. , 2000, European journal of cancer.

[6]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Peters,et al.  Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  A. Paradiso,et al.  Colorectal Clinical Experimental Oncology Laboratory and 2 , 2022 .

[9]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[10]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Maley,et al.  Thymidylate Synthase Protein and p53 mRNA Form an In Vivo Ribonucleoprotein Complex , 1999, Molecular and Cellular Biology.

[12]  Dm Thomas,et al.  5‐FLUOROURACIL: A PHARMACOLOGICAL PARADIGM IN THE USE OF CYTOTOXICS , 1998, Clinical and experimental pharmacology & physiology.

[13]  S. Tsukagoshi,et al.  Immunohistochemical Investigation of Thymidylate Synthase in Cervical Cancer , 1998, Oncology.

[14]  B. Coventry,et al.  The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma. , 1998, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[15]  M. Arends,et al.  DNA mismatch repair and colorectal cancer , 1998, The Journal of pathology.

[16]  F. Monti,et al.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers , 1998, Cell proliferation.

[17]  S. Groshen,et al.  p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  S. Groshen,et al.  p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  L. Bellanca,et al.  The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. , 1998, Anticancer research.

[20]  M. Fukushima,et al.  A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance , 1998, Cancer.

[21]  H. Blomgren,et al.  Immunohistochemical determination of thymidylate synthase in colorectal cancer--methodological studies. , 1997, European journal of cancer.

[22]  F. Bosman,et al.  Clonal growth of colorectal‐carcinoma cell lines transplanted to nude mice , 1997, International journal of cancer.

[23]  L. Johnson,et al.  Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. , 1997, Experimental cell research.

[24]  G. Maley,et al.  Intracellular Location of Thymidylate Synthase and Its State of Phosphorylation* , 1997, The Journal of Biological Chemistry.

[25]  D. Cunningham,et al.  Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. , 1997, British Journal of Cancer.

[26]  C. Allegra,et al.  Identification of in vivo target RNA sequences bound by thymidylate synthase. , 1996, Nucleic acids research.

[27]  A. Kinsella,et al.  p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  P. Johnston,et al.  Thymidylate synthase and drug resistance. , 1995, European journal of cancer.

[29]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. , 1995, European journal of cancer.

[30]  A. Bikfalvi Significance of angiogenesis in tumour progression and metastasis. , 1995, European journal of cancer.

[31]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[32]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Meijer,et al.  Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Storms,et al.  Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae. , 1994, The Journal of biological chemistry.

[35]  K. Danenberg,et al.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. , 1992, Cancer research.

[36]  P. Johnston,et al.  Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. , 1991, Cancer research.

[37]  G. Maley,et al.  Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells. , 1990, Cancer research.

[38]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[39]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.